<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051112</url>
  </required_header>
  <id_info>
    <org_study_id>CLO-SCB-313-CHN-001</org_study_id>
    <nct_id>NCT04051112</nct_id>
  </id_info>
  <brief_title>Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites</brief_title>
  <official_title>A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Clover Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Clover Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The safety and tolerability of single-dose of SCB-313 will be evaluated by&#xD;
           intraperitoneal injection;&#xD;
&#xD;
        2. The safety and tolerability of repeated-dose of SCB-313 will be evaluated by&#xD;
           intraperitoneal injection once a day for 3 days, and the maximum tolerated dose (MTD) of&#xD;
           SCB-313 will be determined;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>28 days after first dosing</time_frame>
    <description>MTD for single and multiple doses of SCB-313</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>28 days after first dosing</time_frame>
    <description>Dose Limiting Toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE/SAE</measure>
    <time_frame>28 days after first dosing</time_frame>
    <description>The severity of the adverse events associated with SCB-313 treatment, the incidence of serious adverse events (SAE), and the severity and incidence of adverse events (TEAE) during the DLT-observation period developed in patients, and the classification is based on the National Cancer Institute General Adverse Event Terminology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 28 days after first dosing</time_frame>
    <description>Occurrence of binding and neutralizing anti-SCB-313 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10</time_frame>
    <description>Maximum SCB-313 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax)</measure>
    <time_frame>Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10</time_frame>
    <description>Time to Cmax of SCB-313</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ([AUC]0-24)</measure>
    <time_frame>Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10</time_frame>
    <description>Area under SCB-313 concentration time curve from zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC 0-inf)</measure>
    <time_frame>Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10</time_frame>
    <description>Area under curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Malignant Ascites</condition>
  <arm_group>
    <arm_group_label>SCB-313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCB-313</intervention_name>
    <description>10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle</description>
    <arm_group_label>SCB-313</arm_group_label>
    <other_name>recombinant human TRAIL-Trimer fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed as malignant solid tumor.&#xD;
&#xD;
          2. Malignant ascites requiring puncture drainage evaluated by investigators, defined as:&#xD;
&#xD;
               1. if tumor cells are detectable in the ascites ,&#xD;
&#xD;
               2. if previous surgical operation reveals extensive abdominal cavity metastasis,&#xD;
&#xD;
               3. if there is image evidence of extensive metastasis in the abdominal cavity,&#xD;
&#xD;
               4. if it is determined by ascites routine and ascites biochemical examination as&#xD;
                  exudate.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 3.&#xD;
&#xD;
          4. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Body weight ≥ 45 kg and body mass index (BMI) &gt;17 kg/m2&#xD;
&#xD;
          7. Adequate hematological function, defined as: (a) Platelet count ≥100×109/L, (b)&#xD;
             Prothrombin time and activated partial thromboplastin time ≤ 1.5 times the upper limit&#xD;
             of normal (ULN), (c) Absolute neutrophil count ≥1.5×109/L, and (d) Hemoglobin ≥ 9&#xD;
             g/dL.&#xD;
&#xD;
          8. Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine&#xD;
             clearance &gt; 50 mL/minute.&#xD;
&#xD;
          9. Adequate liver function, defined as: (a) Aspartate aminotransferase and alanine&#xD;
             aminotransferase ≤ 3 times ULN for patients without liver metastases, or ≤ 5 times ULN&#xD;
             in the presence of liver metastases, and (b) Bilirubin ≤ 2.0 times ULN, unless patient&#xD;
             has known Gilberts syndrome.&#xD;
&#xD;
         10. Albumin ≥ 2.8 g / dL (patient can use albumin to meet the standard)&#xD;
&#xD;
         11. If the serum pregnancy test of a female patient with fertility is negative within 7&#xD;
             days prior to the initial administration, and she is willing to use effective birth&#xD;
             control/contraception method for contraception within 6 months after discontinuation&#xD;
             of SCB-313.( Female patients with fertility exclude women who have undergone&#xD;
             sterilization or menopause, which is defined as a menstrual period that lasts for one&#xD;
             year or more without any other medical reason.) All male and female patients with&#xD;
             reproductive potential must agree to take effective contraceptive measures during the&#xD;
             study period and within 6 months after discontinuation of SCB-313.&#xD;
&#xD;
             Note: Contraceptive methods considered to be effective include: complete abstinence,&#xD;
             intrauterine devices, double barrier contraceptive methods (such as condom plus&#xD;
             spermicide diaphragm), implanted contraceptives, hormonal contraceptives&#xD;
             (contraceptives, implants agent, transdermal patch, hormonal vaginal device or&#xD;
             injection for extended release), or the partner has removed the vas deferens and&#xD;
             confirmed that it is azoospermia&#xD;
&#xD;
         12. Willing to attend follow-up visits according to study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Loculated ascites not amenable to full drainage or benefit from abdominal treatment&#xD;
&#xD;
          2. Acute or chronic infection (such as tuberculosis) requiring antiviral or intravenous&#xD;
             antibiotics within 2 weeks prior to enrollment.&#xD;
&#xD;
          3. Untreated central nervous system metastatic disease, leptomeningeal disease, or cord&#xD;
             compression.&#xD;
&#xD;
          4. Residual adverse events (AEs) ≤ Grade 1 from previous treatment except alopecia.&#xD;
&#xD;
          5. Evidence or suspicion of relevant psychiatric impairment including alcohol or&#xD;
             recreational drug abuse.&#xD;
&#xD;
          6. Myocardial infarction within 6 months prior to treatment, and/or prior diagnoses of&#xD;
             congestive heart failure (New York Heart Association Class III or IV), unstable&#xD;
             angina, unstable cardiac arrhythmia requiring medication, and/or long QT syndrome or&#xD;
             QT/QTc interval &gt;480 msec at baseline.&#xD;
&#xD;
          7. Uncontrolled hypertension defined as systolic blood pressure ≥ 140 mmHg and/or&#xD;
             diastolic blood pressure ≥ 90 mmHg confirmed upon repeated measures.&#xD;
&#xD;
          8. Left ventricular ejection fraction &lt; 50% as determined by echocardiography performed&#xD;
             at screening&#xD;
&#xD;
          9. Hormone therapy or palliative extra abdominal radiotherapy within 1 week, prior&#xD;
             anti-tumor therapy (chemotherapy) within 2 weeks, or other test drug within 4 weeks&#xD;
             prior to enrollment.&#xD;
&#xD;
         10. Major surgery within 4 weeks prior to enrollment.&#xD;
&#xD;
         11. Patient with ileus within 30 days prior to screening.&#xD;
&#xD;
         12. Known portal vein obstruction (due to either prehepatic, hepatic, or posthepatic&#xD;
             condition) which per Investigators judgement, is the primary or significant cause of&#xD;
             ascites.&#xD;
&#xD;
         13. Positive serology test for human immunodeficiency virus type 1 and 2, or known history&#xD;
             of other immunodeficiency disease.&#xD;
&#xD;
         14. Uncontrolled active hepatitis.&#xD;
&#xD;
         15. Scheduled participation in another clinical study involving an investigational product&#xD;
             or device during the course of this study.&#xD;
&#xD;
         16. Previous treatment with a TRAIL-based therapy or Death Receptor (DR) 4/5 agonist&#xD;
             therapy.&#xD;
&#xD;
         17. Known or suspected hypersensitivity to any component of the SCB 313.&#xD;
&#xD;
         18. Any further condition which, according to the investigator, may result in undue risk&#xD;
             of the patient by participating in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200126</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqing Bao</last_name>
      <phone>+86 13701174871</phone>
      <email>olivia.bao@cloverbiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 4, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

